

Special Issue

Selective Antitumor Therapy Based on Nanotechnology

Message from the Guest Editors

This Special Issue aims to publish original research articles and reviews focusing on the latest developments in nanotechnology-based targeted antitumor therapy. This Special Issue welcomes research findings that help to improve cancer therapy by applying strategies based on nanoparticles, such as polymeric nanoparticles, inorganic nanoparticles, liposomes, dendrimers, exosomes, etc.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: targeted drug delivery, theranostics, DNA nanotechnology, nanovectors, gene delivery, gene editing, strategies to overcome drug resistance, immunotherapy, tumor models to validate nanoformulations, the mechanisms of action of nanodevices, nanotoxicology, the preclinical characterization of nanodevices, bio-inspired nanomaterials, exosomes for cancer therapy, etc.

We look forward to receiving your contributions.

Guest Editors

Dr. Rosario M. Sanchez-Martin

GENYO, Centre for Genomics and Oncological Research:
Pfizer/University of Granada/Andalusian Regional Government, 18016
Granada, Spain

Dr. Victoria Cano-Cortés

GENYO Researcher Centre, University of Granada, Granada, Spain

Deadline for manuscript submissions

closed (15 September 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/115580

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).